Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00589459 · ClinicalTrials.gov registry record
Gender Differences in Prevalence of Undiagnosed Diabetes in ACS
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 103
- Enrollment target
NCT00589459: Completed study, sponsored by Yale University.
NCT00589459 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 103 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00589459 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 103 participants
- Enrollment target
Study Summary
The primary goal of this study is to measure the prevalence of undiagnosed pre-diabetes/diabetes among women hospitalized with acute coronary syndromes (ACS) compared to men. Inpatients with confirmed ACS (and no known prior history of diabetes) are invited to return to the Yale Hospital Research Unit 6-8 weeks after hospital discharge for an oral glucose tolerance test to identify individuals with pre-diabetes and diabetes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2001-10-01 |
| Est. Completion | 2008-12-01 |
What the finished NCT00589459 record still lists
NCT00589459 is an observational study that tracks outcomes without assigning an intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00589459 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00589459 about?
NCT00589459 is a clinical study titled "Gender Differences in Prevalence of Undiagnosed Diabetes in ACS". The primary goal of this study is to measure the prevalence of undiagnosed pre-diabetes/diabetes among women hospitalized with acute coronary syndromes (ACS) compared to men. Inpatients with confirmed ACS (and no known prior history of diabetes) are invited to return to the Yale Hospital Research Un...
What is the current status of trial NCT00589459?
This trial is currently completed. The enrollment target is 103 participants. The study started on 2001-10-01. Estimated completion is 2008-12-01.
Who is sponsoring clinical trial NCT00589459?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI